Clinical Trial Update: Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)

View source ↗

Summary

A post-marketing all-case observational study of Gliadel wafer (carmustine implant) in malignant glioma has completed, evaluating safety and real-world outcomes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• GLIADEL wafer (carmustine)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Malignant Glioma | Status: COMPLETED